<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032859</url>
  </required_header>
  <id_info>
    <org_study_id>DMVT-505-3102</org_study_id>
    <nct_id>NCT05032859</nct_id>
  </id_info>
  <brief_title>Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)</brief_title>
  <official_title>A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermavant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermavant Sciences GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy&#xD;
      and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and&#xD;
      adult subjects with atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 8-week double-blind, vehicle-controlled treatment study in which subjects&#xD;
      will be randomized to receive tapinarof cream, 1% or vehicle cream once daily for 8 weeks. At&#xD;
      the end of the 8-week study treatment, qualified subjects will have the option to enroll in&#xD;
      an open-label, long-term extension study for an additional 48 weeks of treatment. Subjects&#xD;
      who do not participate in the open-label, long-term extension study will complete a follow-up&#xD;
      visit approximately one week after the end of treatment in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Following a 30-day screening period, eligible subjects will be randomized at a 2:1 ratio to receive once daily treatment with tapinarof cream, 1% or vehicle cream.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The investigator, study center staff, subject, and sponsor will be blinded to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who have a vIGA-AD score of clear or almost clear (0 or 1) at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥ 75% improvement in EASI from Baseline at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The eczema area and severity index (EASI) scoring system is a clinical tool that takes into account the overall severity of erythema, edema/papulation, lichenification, and excoriation, and the extent of percent body surface area affected with atopic dermatitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in %BSA affected from Baseline at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Assessment of percent body surface area is an estimate of the percentage of total involved skin with atopic dermatitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥ 90% improvement in EASI from Baseline at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The eczema area and severity index (EASI) scoring system is a clinical tool that takes into account the overall severity of erythema, edema/papulation, lichenification, and excoriation, and the extent of percent body surface area affected with atopic dermatitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects ≥ 12 years old with a Baseline PP-NRS score ≥ 4 who achieve ≥ 4-point reduction in the PP NRS from Baseline at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The peak pruritus numeric rating scale is used to quickly assess itch/pruritus severity over a 24-hour period which will be used daily to assess peak pruritus.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>tapinarof cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tapinarof cream, 1%, applied topically once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle cream, applied topically once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tapinarof cream, 1%</intervention_name>
    <description>applied topically once daily</description>
    <arm_group_label>tapinarof cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle cream</intervention_name>
    <description>applied topically once daily</description>
    <arm_group_label>vehicle cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects ages 2 and above with clinical diagnosis of AD&#xD;
&#xD;
          -  Subject with atopic dermatitis covering ≥5% and ≤ 35% of the BSA&#xD;
&#xD;
          -  A vIGA-AD score of ≥3 at screening and baseline&#xD;
&#xD;
          -  An EASI score of ≥6 at screening and baseline&#xD;
&#xD;
          -  Atopic dermatitis present for at least 6 months for ages 6 years old and above or 3&#xD;
             months for ages 2 to 5 years old&#xD;
&#xD;
          -  Female subjects of childbearing potential who are engaging in sexual activity that&#xD;
             could lead to pregnancy should use acceptable birth control methods&#xD;
&#xD;
          -  Must not be pregnant&#xD;
&#xD;
          -  Subject, subject's parent, or legal representative must be capable of giving written&#xD;
             informed consent/assent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunocompromised at screening&#xD;
&#xD;
          -  Chronic or acute systemic or superficial infection requiring treatment with systemic&#xD;
             antibacterials or antifungals within one week prior to baseline visit&#xD;
&#xD;
          -  Significant dermatological or inflammatory condition other than AD that, in the&#xD;
             Investigator's opinion, would make it difficult to interpret data or assessments&#xD;
             during the study&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.0x the upper&#xD;
             limit of normal (ULN).&#xD;
&#xD;
          -  Screening total bilirubin &gt; 1.5x ULN&#xD;
&#xD;
          -  Current or chronic history of liver disease&#xD;
&#xD;
          -  Current or history of cancer within 5 years except for adequately treated cutaneous&#xD;
             basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Subjects who would not be considered suitable for topical therapy&#xD;
&#xD;
          -  Use of any prohibited medication or procedure within the indicated period before the&#xD;
             baseline visit including other investigational product within 30 days or 5 half-lives&#xD;
             of the investigational product (whichever is longer)&#xD;
&#xD;
          -  History of or ongoing serious illness or medical, physical, or psychiatric&#xD;
             condition(s) that, in the Investigator's opinion, may interfere with the subject's&#xD;
             participation in the study, interpretation of results, or ability to understand and&#xD;
             give informed consent.&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  History of sensitivity to the study medications, or components thereof or a history of&#xD;
             drug or other allergy that, in the opinion of the -Investigator or Medical Monitor,&#xD;
             contraindicates their participation&#xD;
&#xD;
          -  Previous known participation in a clinical study with tapinarof (previously known as&#xD;
             GSK2894512 and WBI-1001)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Villalobos</last_name>
    <role>Study Director</role>
    <affiliation>Dermavant Sciences GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Brown, MD, JD</last_name>
    <phone>480-666-0844</phone>
    <email>dermavantclinicaltrials@dermavant.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Dripping Springs</city>
        <state>Texas</state>
        <zip>78620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermavant Clinical Trial</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermavant Clinical Trials</last_name>
      <email>dermavantclinicaltrials@dermavant.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27-33. doi: 10.1159/000365390. Epub 2015 Jan 20.</citation>
    <PMID>25613671</PMID>
  </results_reference>
  <results_reference>
    <citation>Bieber T. Atopic dermatitis. N Engl J Med. 2008 Apr 3;358(14):1483-94. doi: 10.1056/NEJMra074081.</citation>
    <PMID>18385500</PMID>
  </results_reference>
  <results_reference>
    <citation>Cappon GD and Hurtt ME. Developmental toxicity of the kidney. In: Kapp RW and Yyl L, editors. Reproductive Toxicology, Target Organ Series, 3rd edition. New York:Informa Healthcare, 2010:193-204.</citation>
  </results_reference>
  <results_reference>
    <citation>Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005 May-Jun;22(3):192-9. Review.</citation>
    <PMID>15916563</PMID>
  </results_reference>
  <results_reference>
    <citation>Frazier KS and Seely JC. Urinary system. In: Sahota PS, Popp JA, Hardisty JF and Gopinath C, editors. Toxicologic Pathology: Nonclinical Safety Assessment. CRC Press, 2013:421-84.</citation>
  </results_reference>
  <results_reference>
    <citation>Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis. Int J Mol Sci. 2019 Oct 31;20(21). pii: E5424. doi: 10.3390/ijms20215424. Review.</citation>
    <PMID>31683543</PMID>
  </results_reference>
  <results_reference>
    <citation>Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica Supplementum. 1980;92:44-7.</citation>
  </results_reference>
  <results_reference>
    <citation>Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001 Feb;10(1):11-8.</citation>
    <PMID>11168575</PMID>
  </results_reference>
  <results_reference>
    <citation>Kalia YN, Nonato LB, Lund CH, Guy RH. Development of skin barrier function in premature infants. J Invest Dermatol. 1998 Aug;111(2):320-6.</citation>
    <PMID>9699737</PMID>
  </results_reference>
  <results_reference>
    <citation>Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006 Aug;60(8):984-92. Review.</citation>
    <PMID>16893440</PMID>
  </results_reference>
  <results_reference>
    <citation>Nikolovski J, Stamatas GN, Kollias N, Wiegand BC. Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. J Invest Dermatol. 2008 Jul;128(7):1728-36. doi: 10.1038/sj.jid.5701239. Epub 2008 Jan 17.</citation>
    <PMID>18200056</PMID>
  </results_reference>
  <results_reference>
    <citation>Peppers J, Paller AS, Maeda-Chubachi T, Wu S, Robbins K, Gallagher K, Kraus JE. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019 Jan;80(1):89-98.e3. doi: 10.1016/j.jaad.2018.06.047. Epub 2018 Jul 3.</citation>
    <PMID>30554600</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, Coquery CM, Neil J, Pryor WM, Mayhew D, Rajpal DK, Creech K, Furst S, Lee J, Wu D, Rastinejad F, Willson TM, Viviani F, Morris DC, Moore JT, Cote-Sierra J. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans. J Invest Dermatol. 2017 Oct;137(10):2110-2119. doi: 10.1016/j.jid.2017.05.004. Epub 2017 Jun 6.</citation>
    <PMID>28595996</PMID>
  </results_reference>
  <results_reference>
    <citation>Zoetis T, Hurtt ME. Species comparison of anatomical and functional renal development. Birth Defects Res B Dev Reprod Toxicol. 2003 Apr;68(2):111-20. Review.</citation>
    <PMID>12866702</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eczema</keyword>
  <keyword>pediatric</keyword>
  <keyword>tapinarof</keyword>
  <keyword>phase 3</keyword>
  <keyword>topical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

